scholarly journals Impact of pathogen reduction technology on neutralizing antibody titer in COVID-19 convalescent plasma

2021 ◽  
Author(s):  
Massimo Franchini ◽  
Fausto Baldanti ◽  
Elena Percivalle ◽  
Alessandro Ferrari ◽  
Pietro Biasi ◽  
...  
Keyword(s):  
Antibody Titer ◽  
Neutralizing Antibody ◽  
Pathogen Reduction

scholarly journals SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Nanda Kishore Routhu ◽  
Narayanaiah Cheedarla ◽  
Venkata Satish Bollimpelli ◽  
Sailaja Gangadhara ◽  
Venkata Viswanadh Edara ◽  
...  
Keyword(s):  
Antibody Response ◽  
Antibody Titer ◽  
Neutralizing Antibodies ◽  
Rhesus Macaques ◽  
Neutralizing Antibody ◽  
Significant Loss ◽  
Lung Pathology ◽  
Live Virus ◽  
Suitable Candidate ◽  
Immune Pathology

AbstractThere is a great need for the development of vaccines that induce potent and long-lasting protective immunity against SARS-CoV-2. Multimeric display of the antigen combined with potent adjuvant can enhance the potency and longevity of the antibody response. The receptor binding domain (RBD) of the spike protein is a primary target of neutralizing antibodies. Here, we developed a trimeric form of the RBD and show that it induces a potent neutralizing antibody response against live virus with diverse effector functions and provides protection against SARS-CoV-2 challenge in mice and rhesus macaques. The trimeric form induces higher neutralizing antibody titer compared to monomer with as low as 1μg antigen dose. In mice, adjuvanting the protein with a TLR7/8 agonist formulation alum-3M-052 induces 100-fold higher neutralizing antibody titer and superior protection from infection compared to alum. SARS-CoV-2 infection causes significant loss of innate cells and pathology in the lung, and vaccination protects from changes in innate cells and lung pathology. These results demonstrate RBD trimer protein as a suitable candidate for vaccine against SARS-CoV-2.

THE RISK OF POLIOMYELITIS INFECTION AMONG EXPOSED HOSPITAL PERSONNEL

PEDIATRICS ◽  
1956 ◽  
Vol 17 (2) ◽  
pp. 237-246
Author(s):  
Paul F. Wehrle
Keyword(s):  
Antibody Titer ◽  
Neutralizing Antibody ◽  
Striking Difference ◽  
Hospital Personnel ◽  
Poliomyelitis Virus ◽  
Isolation Techniques ◽  
Serologic Evidence ◽  
Acute Poliomyelitis

Hospital personnel caring for acute poliomyelitis patients were studied for serologic evidence of infection by the 3 types of poliomyelitis virus during 1 poliomyelitis season. Although nearly one-third of the personnel were presumably susceptible to the types of poliomyelitis virus present in the cases and an additional and slightly smaller proportion had antibody in low titer, there was no evidence of transfer of infection under these circumstances, as measured by increases in neutralizing antibody titer. The striking difference between the rate of infection among members of households where a case has occurred and among hospital personnel is believed to be due chiefly to a decrease in the infectiousness of cases at the time of hospitalization. The usual hospital isolation techniques appear adequate to prevent transmission of virus from the patient to susceptible personnel under the conditions of hospital exposure.

Is the rabies virus neutralizing antibody titer stable during long-term storage?

2019 ◽  
Vol 32 ◽  
pp. 101468 ◽  
Author(s):  
Lifeng Zhao ◽  
Faming Miao ◽  
Qi Chen ◽  
Ying Wang ◽  
Tongyan Zhao ◽  
...  
Keyword(s):  
Rabies Virus ◽  
Antibody Titer ◽  
Neutralizing Antibody ◽  
Long Term Storage ◽  
Term Storage

scholarly journals Determination of Anti-Adeno-Associated Virus Vector Neutralizing Antibody Titer with an In Vitro Reporter System

2015 ◽  
Vol 26 (2) ◽  
pp. 45-53 ◽  
Author(s):  
Amine Meliani ◽  
Christian Leborgne ◽  
Sabrina Triffault ◽  
Laurence Jeanson-Leh ◽  
Philippe Veron ◽  
...  
Keyword(s):  
Antibody Titer ◽  
Neutralizing Antibody ◽  
Virus Vector ◽  
Reporter System ◽  
Adeno Associated Virus

scholarly journals STUDIES ON PRIMARY ATYPICAL PNEUMONIA

1959 ◽  
Vol 109 (6) ◽  
pp. 545-556 ◽  
Author(s):  
Chien Liu ◽  
Monroe D. Eaton ◽  
James T. Heyl
Keyword(s):  
Antibody Response ◽  
Antibody Titer ◽  
Indirect Method ◽  
Serological Test ◽  
Neutralizing Antibody ◽  
Cold Agglutinin ◽  
Atypical Pneumonia ◽  
Fluorescent Staining ◽  
Cotton Rats

By using the indirect method of fluorescent staining to study the antibody response in patients with primary atypical pneumonai associated with the development of cold agglutinin, it was found that the PAP antibody developed during the 2nd and 3rd week of the illness, and persisted for over a year, and is not related to the cold and streptococcus MG agglutinins. The development of the PAP fluorescent staining antibody paralleled the neutralizing antibody for the PAP virus as tested in cotton rats. The sensitivity of this specific serological test was indicated by the observation that 67 to 92 per cent of the patients in several outbreaks of PAP showed a rise of antibody titer during convalescence. Absorption of the sera with various tissue powders did not affect the PAP antibody detected by this method.

scholarly journals Human H5N2 Avian Influenza Infection in Japan and the Factors Associated with High H5N2-Neutralizing Antibody Titer

2008 ◽  
Vol 18 (4) ◽  
pp. 160-166 ◽  
Author(s):  
Tsuyoshi Ogata ◽  
Yoshinao Yamazaki ◽  
Nobuhiko Okabe ◽  
Yosikazu Nakamura ◽  
Masato Tashiro ◽  
...  
Keyword(s):  
Avian Influenza ◽  
Antibody Titer ◽  
Influenza Infection ◽  
Neutralizing Antibody ◽  
Factors Associated

scholarly journals Individuals who were mildly symptomatic following infection with SARS-CoV-2 B.1.1.28 have neutralizing antibodies to the P.1 variant.

2021 ◽  
Author(s):  
Maria Cassia Mendes-Correa ◽  
Lucy Santos Santos Vilas-Boas ◽  
Ana Luiza Bierrenbach ◽  
Anderson Vincente de Paula ◽  
Tania Regina Tozetto-Mendoza ◽  
...  
Keyword(s):  
Antibody Titer ◽  
Neutralizing Antibodies ◽  
Neutralizing Antibody ◽  
Original Strain ◽  
Ancestral Strain

Abstract Objectives: To evaluate if antibodies induced by infection with SARS-CoV-2 B.1.128 neutralize the P.1 variant. Methods: Convalescent sera from 60 individuals who had mild symptoms that did not require hospitalization following a documented SARS-CoV-2 infection (B.1.128 lineage) were assayed for neutralizing antibody titer against their original strain and against the SARS-CoV-2 P.1 variant. Results: Fifty-six (94%) and 50 (84 %) sera were positive for neutralizing antibodies against the ancestral and P.1 strains, respectively, and remained positive throughout the 6-week study period. Neutralization titers were consistently higher against the ancestral strain (p≤ 0.001), but in the majority of patients (57.8%) differences did not differ by more than a single dilution. Conclusions: Neutralizing antibodies that were generated following a mild infection with SARS-CoV-2 B.1.128 were effective in vitro, and likely protective, against the SARS-CoV-2 P.1. variant in the majority of individuals.

scholarly journals ChAdOx1 nCoV-19 (AZD1222) protects hamsters against SARS-CoV-2 B.1.351 and B.1.1.7 disease

2021 ◽  
Author(s):  
Robert J. Fischer ◽  
Neeltje van Doremalen ◽  
Danielle R. Adney ◽  
Claude Kwe Yinda ◽  
Julia R. Port ◽  
...  
Keyword(s):  
Single Dose ◽  
Antibody Titer ◽  
Vaccine Efficacy ◽  
Infectious Virus ◽  
Neutralizing Antibody ◽  
Subgenomic Rna ◽  
Fold Reduction ◽  
Histopathological Evaluation ◽  
Gross Lesions ◽  
Pulmonary Pathology

AbstractWe investigated ChAdOx1 nCoV-19 (AZD1222) vaccine efficacy against SARS-CoV-2 variants of concern (VOCs) B.1.1.7 and B.1.351 in Syrian hamsters. We previously showed protection against SARS-CoV-2 disease and pneumonia in hamsters vaccinated with a single dose of ChAdOx1 nCoV-19. Here, we observed a 9.5-fold reduction of virus neutralizing antibody titer in vaccinated hamster sera against B.1.351 compared to B.1.1.7. Vaccinated hamsters challenged with B.1.1.7 or B.1.351 did not lose weight compared to control animals. In contrast to control animals, the lungs of vaccinated animals did not show any gross lesions. Minimal to no viral subgenomic RNA (sgRNA) and no infectious virus was detected in lungs of vaccinated animals. Histopathological evaluation showed extensive pulmonary pathology caused by B.1.1.7 or B.1.351 replication in the control animals, but none in the vaccinated animals. These data demonstrate the effectiveness of the ChAdOx1 nCoV-19 vaccine against clinical disease caused by B.1.1.7 or B.1.351 VOCs.

Sign in / Sign up

Export Citation Format

Share Document